Trial · NCT04071951
Pharmacist Intervention to Reduce Post-Hospitalization Utilization
NCT04071951, Not applicable, Active not recruiting, Cedars-Sinai Medical Center; results first posted 2024-10-29
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Pharmacist Intervention to Reduce Post-Hospitalization Utilization. Trials, record NCT04071951. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04071951
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacist Intervention to Reduce Post-Hospitalization Utilization
- NCT number
- NCT04071951
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 6,478 participants, actual
- Lead sponsor
- Cedars-Sinai Medical Center
- Conditions
- Nonadherence, Patient, Polypharmacy, Readmission
- Interventions
- Pharmacist-led Hospital Discharge Care Intervention
- First posted
- 2019-08-28
- Last updated
- 2026-04-02
- Results first posted
- 2024-10-29
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Based on EHR Data and CMS Claims) | Hospitalization to a hospital or ED visit within 30 days of discharge (checking at least all same state facilities) | A patient is readmitted to a hospital (including observation) or has an ED visit within 30 days of discharge (including all hospitals at least statewide), excluding foreseen readmissions, which include: transplants, chemotherapy or radiotherapy, treatment follow-up, rehabilitation care, and planned operations |
| Secondary | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital) | Hospitalization to the same hospital or ED visit within 30 days of discharge (including other facilities in the system using the same electronic health record instance) | A patient is readmitted to the same hospital (including observation stays) or has an ED visit within 30 days of discharge, excluding foreseen readmissions, which include: transplants, chemotherapy or radiotherapy, treatment follow-up, rehabilitation care, and planned operations |
| Secondary | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital) Stratified by Receipt of Different Intervention Components | Hospitalization to the same hospital or ED visit within 30 days of discharge | A patient is readmitted to the same hospital (including observation stays) or has an ED visit within 30 days of discharge. This outcome measure will analyze the outcome by whether patients received the intervention components (admission medication reconciliation, medication regimen review, actions to improve adherence, side effect management, drug level monitoring, discharge medication reconciliation, patient/caregiver education, motivational interviewing, post-discharge follow-up phone call, medication access, communication with PCP, communication with communication pharmacy, other). The investigators will exclude foreseen readmissions, which include: transplants, chemotherapy or radiotherapy, treatment follow-up, rehabilitation care, and planned operations. |
| Secondary | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital) Stratified by Whether Patient Has a Diagnosis of Congestive Heart Failure at Admission | Hospitalization to the same hospital or ED visit within 30 days of discharge | A patient is readmitted to the same hospital (including observation stays) or has an ED visit within 30 days of discharge stratified by whether patient has a diagnosis of congestive heart failure at admission. The investigators will exclude foreseen readmissions, which include: transplants, chemotherapy or radiotherapy, treatment follow-up, rehabilitation care, and planned operations. |
| Secondary | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital), Stratified by Whether Patient Has Three or More High Risk Medications (Anticoagulants, Antiplatelets, Insulin, Oral Hypoglycemics) Prior to Admission | Hospitalization to the same hospital or ED visit within 30 days of discharge | A patient is readmitted to the same hospital (including observation stays) or has an ED visit within 30 days of discharge stratified by whether patient has three or more high risk medications (anticoagulants, antiplatelets, insulin, oral hypoglycemics) prior to admission. The investigators will exclude foreseen readmissions, which include: transplants, chemotherapy or radiotherapy, treatment follow-up, rehabilitation care, and planned operations. |
| Secondary | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital), Stratified by Whether Patient Has 10 or More Medications Prior to Admission | Hospitalization to the same hospital or ED visit within 30 days of discharge | A patient is readmitted to the same hospital (including observation stays) or has an ED visit within 30 days of discharge stratified by whether patient has 10 or more medications prior to admission. The investigators will exclude foreseen readmissions, which include: transplants, chemotherapy or radiotherapy, treatment follow-up, rehabilitation care, and planned operations. |
| Secondary | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital) Stratified by Study Site | Hospitalization to the same hospital or ED visit within 30 days of discharge | A patient is readmitted to the same hospital (including observation stays) or has an ED visit within 30 days of discharge stratified by study site. The investigators will exclude foreseen readmissions, which include: transplants, chemotherapy or radiotherapy, treatment follow-up, rehabilitation care, and planned operations. |
| Secondary | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital) Stratified by Patient Medication Adherence and Literacy | Hospitalization to the same hospital or ED visit within 30 days of discharge | A patient is readmitted to the same hospital (including observation stays) or has an ED visit within 30 days of discharge stratified by patient medication adherence and literacy (as assessed by study pharmacists, in addition to using limited English proficiency as a proxy for low medication literacy). The investigators will exclude foreseen readmissions, which include: transplants, chemotherapy or radiotherapy, treatment follow-up, rehabilitation care, and planned operations. |
| Secondary | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital) Stratified by Quintiles of Patient Socioeconomic Status (Estimated Via Median Income of Home Census Tract) | Hospitalization to the same hospital or ED visit within 30 days of discharge | A patient is readmitted to the same hospital (including observation stays) or has an ED visit within 30 days of discharge stratified by patient socioeconomic status (estimated via median income of home census tract). The investigators will exclude foreseen readmissions, which include: transplants, chemotherapy or radiotherapy, treatment follow-up, rehabilitation care, and planned operations. |
| Secondary | Rate (%) of New BZR Discharge Prescriptions Among Patients Not Taking BZRs Prior to Admission | Patients not taking BZRs prior to admission | A dichotomous variable for a new discharge prescription of BZRs among patients not taking BZRs prior to admission. |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes19
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Including Hospitals at Least Statewide) | Hospitalization to a hospital or ED visit within 30 days of discharge (checking at least all same state facilities) | note that to obtain outside hospital data, analysis was restricted to 4602 patients with fee-for-service Medicare (for whom all-hospital claims data was available) | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital) | Hospitalization to the same hospital or ED visit within 30 days of discharge | |||
| SECONDARY | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital) Stratified by Receipt of Different Intervention Components | Hospitalization to the same hospital or ED visit within 30 days of discharge | |||
| SECONDARY | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital) Stratified by Whether Patient Has a Diagnosis of Congestive Heart Failure at Admission | Hospitalization to the same hospital or ED visit within 30 days of discharge | |||
| SECONDARY | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital), Stratified by Whether Patient Has Three or More High Risk Medications (Anticoagulants, Antiplatelets, Insulin, Oral Hypoglycemics) Prior to Admission | Hospitalization to the same hospital or ED visit within 30 days of discharge | |||
| SECONDARY | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital), Stratified by Whether Patient Has 10 or More Medications Prior to Admission | Hospitalization to the same hospital or ED visit within 30 days of discharge | |||
| SECONDARY | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital) Stratified by Study Site | Hospitalization to the same hospital or ED visit within 30 days of discharge | |||
| SECONDARY | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital) Stratified by Patient Medication Adherence and Literacy | Hospitalization to the same hospital or ED visit within 30 days of discharge | |||
| SECONDARY | Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Same-hospital) Stratified by Quintiles of Patient Socioeconomic Status (Estimated Via Median Income of Home Census Tract) | Hospitalization to the same hospital or ED visit within 30 days of discharge | |||
| SECONDARY | Rate (%) of New BZR Discharge Prescriptions Among Patients Not Taking BZRs Prior to Admission | Patients not taking BZRs prior to admission |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 outcomesResults by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Including Hospitals at Least Statewide) | Pharmacist Arm | 595 | Participants | ||
| Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Including Hospitals at Least Statewide) | Usual Care | 610 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pharmacist Arm | 3,239 | |
| Overall Study | STARTED | Usual Care | 3,239 | |
| Overall Study | COMPLETED | Pharmacist Arm | 3,213 | |
| Overall Study | COMPLETED | Usual Care | 3,215 | |
| Overall Study | NOT COMPLETED | Pharmacist Arm | 26 | |
| Overall Study | NOT COMPLETED | Usual Care | 24 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | 90-day post-discharge utilization | General disorders | Pharmacist Arm | 1,155 | 3,239 | |
| serious | 90-day post-discharge utilization | General disorders | Usual Care | 1,104 | 3,239 | |
| serious | 30-day post-discharge utilization (same hospital) | General disorders | Pharmacist Arm | 662 | 3,239 | |
| serious | 30-day post-discharge utilization (same hospital) | General disorders | Usual Care | 666 | 3,239 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pharmacist Arm | 330 | 3,239 |
| Total, all-cause mortality | Usual Care | 334 | 3,239 |
| Total, other adverse events | Pharmacist Arm | 0 | 3,239 |
| Total, other adverse events | Usual Care | 0 | 3,239 |
| Total, serious adverse events | Pharmacist Arm | 1,485 | 3,239 |
| Total, serious adverse events | Usual Care | 1,438 | 3,239 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AG058911 | A Multicenter RCT of Pharmacist-Directed Transitional Care to Reduce Post-Hospitalization Utilization | PEVNICK, JOSHUA M | CEDARS-SINAI MEDICAL CENTER | NATIONAL INSTITUTE ON AGING | 2018 to 2022 |
Source NIH RePORTER
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Pharmacist Arm vs Usual Care: Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Including Hospitals at Least Statewide) | Trial comparisons |
| Pharmacist Arm vs Usual Care: deaths from any cause | Trial comparisons |
| Pharmacist Arm vs Usual Care: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04071951
GET https://conductscience.org/api/trials/v1/NCT04071951/registered